Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Depreciation and Depletion (2016 - 2020)

Ptc Therapeutics (PTCT) has 9 years of Depreciation and Depletion data on record, last reported at -$24.5 million in Q4 2020.

  • For Q4 2020, Depreciation and Depletion fell 34.53% year-over-year to -$24.5 million; the TTM value through Dec 2020 reached $6.6 million, up 40.43%, while the annual FY2024 figure was $14.9 million, 7.19% up from the prior year.
  • Depreciation and Depletion reached -$24.5 million in Q4 2020 per PTCT's latest filing, down from $11.6 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $11.6 million in Q3 2020 and bottomed at -$24.5 million in Q4 2020.
  • Average Depreciation and Depletion over 5 years is $975000.0, with a median of $3.4 million recorded in 2016.
  • The widest YoY moves for Depreciation and Depletion: up 1166.3% in 2017, down 1247.39% in 2017.
  • A 5-year view of Depreciation and Depletion shows it stood at $823000.0 in 2016, then crashed by 1247.39% to -$9.4 million in 2017, then tumbled by 77.02% to -$16.7 million in 2018, then fell by 8.9% to -$18.2 million in 2019, then tumbled by 34.53% to -$24.5 million in 2020.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were -$24.5 million in Q4 2020, $11.6 million in Q3 2020, and $10.2 million in Q2 2020.